Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

169
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
169
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

146
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variability in Cardiac Stress Test Interpretation: Agreement Between Enrollment Sites and Core Laboratories in the Global ISCHEMIA Trial.

Circulation. Population health and outcomes·2026
Same author

The association of eicosanoids with lung structure and function: Findings from the Multi-Ethnic Study of Atherosclerosis lung study and Framingham Heart Study.

PloS one·2026
Same author

Large-scale proteomics in early pregnancy and timing of onset of hypertensive disorders of pregnancy.

medRxiv : the preprint server for health sciences·2026
Same author

A Machine Learning Driven Approach to Quantifying Coronary Artery Tortuosity.

JACC. Advances·2026
Same author

Menopausal Age, Number of Live Births, and Risk of Atrial Fibrillation: The Cardiovascular Health Study.

Journal of the American Heart Association·2026
Same author

Generation of complementary linear frequency-modulated microwave signals based on an on-chip Sagnac dual-loop spectral shaper.

Optics express·2026

Related Experiment Video

Updated: Jun 27, 2025

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.2K

Sex Differences in Pulmonary Hypertension and Associated Right Ventricular Dysfunction.

Janet I Ma, Ndidi Owunna, Nona M Jiang

    Medrxiv : the Preprint Server for Health Sciences
    |May 7, 2024
    PubMed
    Summary

    Women with pulmonary hypertension (PH) show distinct hemodynamic subtypes and better right ventricular (RV) function compared to men. These sex differences in PH impact RV function and reduce heart failure hospitalization risk in women.

    More Related Videos

    Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
    07:38

    Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

    Published on: January 20, 2023

    3.5K
    Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
    09:40

    Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

    Published on: May 13, 2019

    10.5K

    Related Experiment Videos

    Last Updated: Jun 27, 2025

    Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
    08:34

    Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

    Published on: November 18, 2018

    7.2K
    Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
    07:38

    Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

    Published on: January 20, 2023

    3.5K
    Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
    09:40

    Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

    Published on: May 13, 2019

    10.5K

    Area of Science:

    • Cardiology
    • Pulmonary Medicine
    • Sex Differences in Medicine

    Background:

    • Previous research focused on sex differences in pulmonary arterial hypertension (PAH), leaving other pulmonary hypertension (PH) hemodynamic subtypes less explored.
    • This study investigates sex-based variations across all PH hemodynamic subtypes and their association with right ventricular (RV) function.

    Conclusions:

    • Significant sex differences exist in PH prevalence across hemodynamic subtypes, with women more often having pre-capillary PH and men more often having post-capillary PH.
    • Women with PH exhibit enhanced RV function and a reduced risk of heart failure hospitalization compared to men.
    • Understanding these sex disparities is crucial for refining risk stratification and developing targeted, sex-specific therapies for PH.